Phase 1 Lung Cancer Trial, Not Yet Recruiting NCT07318636 Sponsor: The First Affiliated Hospital of Guangzhou Medical University Condition: Lung Cancer
Back to Lung Cancer

Phase 1 Lung Cancer Trial, Not Yet Recruiting

NCT07318636
Not Yet Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are able to understand and willingly sign a written consent form.
  • Men or women aged 18 years or older.
  • People who have been confirmed through tissue or cell testing to have a type of lung cancer called non-small cell lung cancer (NSCLC) that can be surgically removed, at a stage between IB and IIIA (based on a standard cancer staging system).
  • People whose NSCLC has not been treated before with any cancer-fighting medicines given throughout the body.
  • People whose lung cancer does not have certain specific genetic changes known as EGFR mutations (exon 19 deletion or exon 21 L858R) or ALK gene rearrangements.
  • People who have at least one tumour that can be measured using standard imaging criteria (confirm with trial site).
  • People with an estimated life expectancy of more than 6 months.
  • People with a good general level of physical functioning, rated 0 or 1 on a standard scale used in cancer research (meaning fully active or able to carry out light work).
  • People with blood counts and kidney and liver function within acceptable ranges.
  • Women who could become pregnant must have a negative pregnancy test before starting the study treatment.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have previously received any cancer-fighting medicines given throughout the body.
  • People whose lung cancer is known to have certain specific genetic changes (EGFR mutations or ALK gene rearrangements).
  • People who have an active, known, or suspected condition where the immune system attacks the body.
  • People who have a lung condition involving scarring or inflammation of the lung tissue (interstitial lung disease).
  • People with a medical condition, ongoing treatment, or abnormal test results that, in the trial doctor's judgement, could affect study results or make participation unsafe or unsuitable.
  • People whose lung cancer cannot be surgically removed or has spread to other parts of the body.
  • People who have had a serious heart event, an unstable irregular heartbeat, or unstable chest pain within the 3 months before starting the study treatment.
  • Women who are pregnant, breastfeeding, or who could become pregnant and are unwilling to use effective contraception throughout the study.
  • People whom the trial doctor considers unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026

Contact this trial

Phone: 020-83062807

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
20 January 2026
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs); Dose Limiting Toxicities (DLTs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov